D
OKYO Pharma Limited OKYO
$2.37 $0.041.72% NASDAQ
Recommendation
Prev Close
$2.37
Volume
580
Avg Vol (90D)
174,264
Market Cap
$89.14M
Dividend & Yield
--
52-Week Range
$0.85 - $3.35
P/E (TTM)
--
EPS (TTM)
-$0.1244
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street Zen
8/10/2025 - MarketBeat
Lucid Capital Sees Potential in Okyo Pharma (OKYO) with Buy Rating
7/31/2025 - GuruFocus
Okyo Pharma initiated with bullish view at Lucid Capital, here's why
7/31/2025 - The Fly
Dauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)
7/29/2025 - Ticker Report
OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI
7/19/2025 - Proactive Investors - UK
Small cap wrap: Digi Power X, American Resources, OKYO Pharma, Lisata Therapeutics...
7/17/2025 - Proactive Investors - UK
OKYO Pharma Secures Non-Dilutive Funding to Boost Urcosimod Development OKYO Stock News
7/17/2025 - GuruFocus
OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development
7/17/2025 - TipRanks Financial Blog
OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy
7/17/2025 - Proactive Investors - UK
OKYO Pharma bolsters ocular pain program with $1.9M non-dilutive financing
7/17/2025 - Proactive Investors - UK
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of ...
7/17/2025 - GuruFocus
Okyo Pharma receives $1.9M in non-dilutive funding
7/17/2025 - The Fly
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
7/17/2025 - Globe Newswire
Small cap wrap: OKYO Pharma, North Bay Resources, Nevis Brands, Nextech3D.ai...
7/16/2025 - Proactive Investors - UK
OKYO Pharma reports results from Urcosimod trial
7/16/2025 - Seeking Alpha - Healthcare
OKYO Pharma reports positive Phase 2 data in treating Neuropathic Corneal Pain
7/16/2025 - Proactive Investors - UK
OKYO Pharma's Urcosimod Shows Promising Results in Phase 2 NCP Trial OKYO Stock News
7/16/2025 - GuruFocus
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic ...
7/16/2025 - GuruFocus
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic ...
7/16/2025 - GuruFocus
OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain
7/16/2025 - TipRanks Financial Blog
OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain
7/16/2025 - Proactive Investors - UK
Okyo Pharma reports Phase 2 clinical trial results for urcosimod
7/16/2025 - The Fly
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
7/16/2025 - Globe Newswire
okyo sets sights first approval neuropathic eye pain after phase 2 win
7/16/2025 - FierceBiotech.com - Biotech
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% - Here's Why
7/10/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$7.09M
EBIT (TTM)
-$7.09M
Net Income (TTM)
-$4.71M
Balance Sheet
Total Assets (Q)
$3.68M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$9.23M
Book Value Per Share (Q)
-$0.1541
Cash Flow
Cash from Operations (TTM)
-$1.81M
Cash from Investing (TTM)
-$1.20K
Cash from Financing (TTM)
$2.66M
Net Change in Cash (TTM)
$734.20K
Filings
Filing Date
Friday, July 18, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Jan 26 and 30 (est)
Price History
Loading...
Beta
0.37
7-Day Total Return
-10.23%
30-Day Total Return
-8.14%
60-Day Total Return
26.74%
90-Day Total Return
111.61%
Year to Date Total Return
109.73%
1-Year Total Return
127.88%
2-Year Total Return
20.30%
3-Year Total Return
21.54%
5-Year Total Return
231.47%
52-week Low
Aug 23, 2024 - $0.85
52-week High
Aug 08, 2025 - $3.35
Valuation
Market Cap
$89.14M - Micro Cap
Enterprise Value
$87.58M
Price/Sales (TTM)
--
Price/Book (Q)
-15.38
Dividends and Shares
Shares Outstanding
45.40
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
okyopharma.com
Phone Number
44 20 7495 2379
Address
14/15 Conduit St
London, W1S 2XJ
Country
United Kingdom
Year Founded
2007
Business Description
Sector
Materials
Industry
Materials
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead... more
NASDAQ 08/22/2025 4:00PM Eastern Quotes delayed